The group has now 88 approvals and has so far filed 216 ANDAs
New Delhi January 31, 2014: Drug firm Cadila Healthcare today said it has received US health regulator’s nod to market Etodolac extended release tablets, used in the treatment of arthritis, in the American market.
The company has received final approval from the US Food and Drug Administration (USFDA) to market Etodolac extended release tablets in strengths of 400mg, 500mg and 600 mg, Cadila Healthcare said in a filing to the BSE.
The drug is prescribed for treatment of juvenile arthritis, rheumatoid arthritis and osteoarthritis, it added.
The group has now 88 approvals and has so far filed 216 abbreviated new drug applications (ANDAs).
Cadila scrip closed at Rs 809.15 on the BSE, down 0.25%.-Business standard
- This specialized division empowers patients with neurological disorders to reclaim their mobility through a…
SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…
Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…
DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…
Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…
Hyderabad, April 13, 2024: Ankura Hospital for Women and Children is proud to announce a remarkable medical…